162 related articles for article (PubMed ID: 10533596)
1. Homocysteine and endothelial function.
Doshi SN; Goodfellow J; Lewis MJ; McDowell IF
Cardiovasc Res; 1999 Jun; 42(3):578-82. PubMed ID: 10533596
[No Abstract] [Full Text] [Related]
2. Homocysteine and large arteries.
Guldener CV; Stehouwer CDA
Adv Cardiol; 2007; 44():278-301. PubMed ID: 17075216
[TBL] [Abstract][Full Text] [Related]
3. Effects of methionine-induced hyperhomocysteinemia on endothelium-dependent vasodilation and oxidative status in healthy adults.
Chao CL; Kuo TL; Lee YT
Circulation; 2000 Feb; 101(5):485-90. PubMed ID: 10662744
[TBL] [Abstract][Full Text] [Related]
4. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA.
Lentz SR; Rodionov RN; Dayal S
Atheroscler Suppl; 2003 Dec; 4(4):61-5. PubMed ID: 14664904
[TBL] [Abstract][Full Text] [Related]
5. Homocysteine and endothelial function in human studies.
Moat SJ; McDowell IF
Semin Vasc Med; 2005 May; 5(2):172-82. PubMed ID: 16047269
[TBL] [Abstract][Full Text] [Related]
6. Can mild-to-moderate hyperhomocysteinaemia impair endothelial function in the absence of other risk factors for cardiovascular disease?
Honing ML; Stehouwer CD
Clin Sci (Lond); 2004 Apr; 106(4):345-6. PubMed ID: 14656217
[TBL] [Abstract][Full Text] [Related]
7. New cardiovascular risk factors: homocysteine and vitamins involved in homocysteine metabolism.
De Caterina R; Zampolli A; Madonna R; Fioretti P; Vanuzzo D
Ital Heart J; 2004 Jun; 5 Suppl 6():19S-24S. PubMed ID: 15185912
[TBL] [Abstract][Full Text] [Related]
8. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.
Sydow K; Hornig B; Arakawa N; Bode-Böger SM; Tsikas D; Münzel T; Böger RH
Vasc Med; 2004 May; 9(2):93-101. PubMed ID: 15521698
[TBL] [Abstract][Full Text] [Related]
9. Homocysteine impairs coronary artery endothelial function by inhibiting tetrahydrobiopterin in patients with hyperhomocysteinemia.
He L; Zeng H; Li F; Feng J; Liu S; Liu J; Yu J; Mao J; Hong T; Chen AF; Wang X; Wang G
Am J Physiol Endocrinol Metab; 2010 Dec; 299(6):E1061-5. PubMed ID: 20858749
[TBL] [Abstract][Full Text] [Related]
10. Hyperhomocysteinemia and cardiovascular disease in animal model.
Azad MAK; Huang P; Liu G; Ren W; Teklebrh T; Yan W; Zhou X; Yin Y
Amino Acids; 2018 Jan; 50(1):3-9. PubMed ID: 29018979
[TBL] [Abstract][Full Text] [Related]
11. S-adenosylmethionine and 5-methyltetrahydrofolate are associated with endothelial function after controlling for confounding by homocysteine: the Hoorn Study.
Spijkerman AM; Smulders YM; Kostense PJ; Henry RM; Becker A; Teerlink T; Jakobs C; Dekker JM; Nijpels G; Heine RJ; Bouter LM; Stehouwer CD
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):778-84. PubMed ID: 15692102
[TBL] [Abstract][Full Text] [Related]
12. ADMA and hyperhomocysteinemia.
Dayal S; Lentz SR
Vasc Med; 2005 Jul; 10 Suppl 1():S27-33. PubMed ID: 16444866
[TBL] [Abstract][Full Text] [Related]
13. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction.
van Guldener C; Stehouwer CD
Semin Thromb Hemost; 2000; 26(3):281-9. PubMed ID: 11011845
[TBL] [Abstract][Full Text] [Related]
14. Homocysteine and coronary microcirculation: is it a microvasculopathic agent?
Turhan H; Aksoy Y; Yetkin E
Int J Cardiol; 2006 Jun; 110(2):269-70. PubMed ID: 16325281
[No Abstract] [Full Text] [Related]
15. [Homocysteine: relations to ischemic cardiovascular diseases].
Piolot A; Nadler F; Parez N; Jacotot B
Rev Med Interne; 1996; 17(1):34-45. PubMed ID: 8677383
[TBL] [Abstract][Full Text] [Related]
16. Murine models of hyperhomocysteinemia and their vascular phenotypes.
Dayal S; Lentz SR
Arterioscler Thromb Vasc Biol; 2008 Sep; 28(9):1596-605. PubMed ID: 18556571
[TBL] [Abstract][Full Text] [Related]
17. [Homocysteine and rheumatic disease].
Tinazzi I; Caramaschi P; Patuzzo G; Bambara LM; Biasi D
Recenti Prog Med; 2007 Dec; 98(12):646-52. PubMed ID: 18369042
[TBL] [Abstract][Full Text] [Related]
18. Homocysteine-Induced Endothelial Dysfunction.
Lai WK; Kan MY
Ann Nutr Metab; 2015; 67(1):1-12. PubMed ID: 26201664
[TBL] [Abstract][Full Text] [Related]
19. Is homocysteine an iron-dependent cardiovascular risk factor?
Sullivan JL
Kidney Int; 2006 Feb; 69(4):642-4. PubMed ID: 16467888
[TBL] [Abstract][Full Text] [Related]
20. Reduced adenosine receptor stimulation as a pathogenic factor in hyperhomocysteinemia.
Riksen NP; Rongen GA; Blom HJ; Boers GH; Smits P
Clin Chem Lab Med; 2005; 43(10):1001-6. PubMed ID: 16197288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
